Dr. Michael Pulsipher, MD
Claim this profileChildren's Hospital Los Angeles
Studies Leukemia
Studies Lymphoblastic Leukemia-Lymphoma
16 reported clinical trials
31 drugs studied
Area of expertise
1Leukemia
CD19 positive
CD22 positive
HLA-A positive
2Lymphoblastic Leukemia-Lymphoma
CD19 positive
HLA-A positive
HLA-A negative
Affiliated Hospitals
Clinical Trials Michael Pulsipher, MD is currently running
T Cell-Depleted Stem Cell Transplant
for Leukemia
This phase II trial studies how well naive T-cell depletion works in preventing chronic graft-versus-host disease in children and young adults with blood cancers undergoing donor stem cell transplant. Sometimes the transplanted white blood cells from a donor attack the body's normal tissues (called graft versus host disease). Removing a particular type of T cell (naive T cells) from the donor cells before the transplant may stop this from happening.
Recruiting1 award Phase 222 criteria
CAR T-Cell Therapy
for Leukemia and Lymphoma
Patients with relapsed or refractory leukemia or lymphoma are often refractory to further chemotherapy. In this study, the investigators will attempt to use T cells obtained directly from the patient, which can be genetically engineered to express a chimeric antigen receptor (CAR). The CAR used in this study can recognize CD22, a protein expressed on the surface of leukemia and lymphoma cells. The phase 1 part of this study will determine the safety and appropriate dose level of these CAR T cells, and the phase 2 part of the study will determine how effective this CAR T cell therapy is. Both patients who have never had prior CAR T cell therapy and those who have had prior CAR T cell therapy may be eligible to participate in this study.
Recruiting1 award Phase 1 & 215 criteria
More about Michael Pulsipher, MD
Clinical Trial Related5 years of experience running clinical trials · Led 16 trials as a Principal Investigator · 8 Active Clinical TrialsTreatments Michael Pulsipher, MD has experience with
- Fludarabine
- Tacrolimus
- Cyclophosphamide
- Busulfan
- Methotrexate
- Tisagenlecleucel
Breakdown of trials Michael Pulsipher, MD has run
Leukemia
Lymphoblastic Leukemia-Lymphoma
Acute Lymphoblastic Leukemia
Lymphoid Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Michael Pulsipher, MD specialize in?
Michael Pulsipher, MD focuses on Leukemia and Lymphoblastic Leukemia-Lymphoma. In particular, much of their work with Leukemia has involved CD19 positive patients, or patients who are CD22 positive.
Is Michael Pulsipher, MD currently recruiting for clinical trials?
Yes, Michael Pulsipher, MD is currently recruiting for 8 clinical trials in Los Angeles California. If you're interested in participating, you should apply.
Are there any treatments that Michael Pulsipher, MD has studied deeply?
Yes, Michael Pulsipher, MD has studied treatments such as Fludarabine, Tacrolimus, Cyclophosphamide.
What is the best way to schedule an appointment with Michael Pulsipher, MD?
Apply for one of the trials that Michael Pulsipher, MD is conducting.
What is the office address of Michael Pulsipher, MD?
The office of Michael Pulsipher, MD is located at: Children's Hospital Los Angeles, Los Angeles, California 90027 United States. This is the address for their practice at the Children's Hospital Los Angeles.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.